ReShape Lifesciences Secures FDA PMA Supplement Approval For Next-Generation Lap-Band 2.0 FLEX
Portfolio Pulse from Benzinga Newsdesk
ReShape Lifesciences has received FDA PMA Supplement Approval for its next-generation Lap-Band 2.0 FLEX. The company is gearing up for the U.S. launch of the product and plans to provide updates on its progress.
December 12, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ReShape Lifesciences has secured FDA approval for its Lap-Band 2.0 FLEX, which is a positive development for the company as it prepares for the U.S. product launch.
FDA approval is a significant milestone for medical device companies, often leading to increased investor confidence and potential stock price appreciation. The approval of Lap-Band 2.0 FLEX positions ReShape Lifesciences favorably for its upcoming U.S. launch, which could drive revenue growth and enhance its market position.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100